In line with these mechanisms, Mazzu et al. demonstrated that RRM2 downregulation in prostate cancer cells induces widespread transcriptomic and phosphoproteomic changes, including the suppression of key genes enriched in the MYC, E2F and cell cycle pathways and the activation of genes related to the p53 and apoptosis pathways (Mazzu et al. 2019, 2020). The gene discussed is RRM2; the disease is Familial prostate cancer.